Lowers the risk of cardiovascular mortality and heart failure hospitalizations. ANDA 214110, held by Zhejiang Jutai Pharm. Metoprolol Succinate.
As of Nov 16, 2026, ANDA 214110 (Metoprolol Succinate), held by Zhejiang Jutai Pharm, was first approved by FDA on Jul 26, 2024, with 0 approved supplements and 0 published complete response letters.
Metoprolol succinate, is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Angina Pectoris. Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 26, 2024 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 50MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 100MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 200MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 25MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters